Targeting the Src N-terminal regulatory element in cancer
Article in Oncotarget (May 2023)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition.
Article in American Journal of Cancer Research (March 2023)
pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer
Article in Acta Biomaterialia (October 2022)